While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to ...

The companies’ new effort would bypass traditional middlemen to cut the drug’s monthly cost from a list price of around $606 ...

PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

(Reuters) -US drugmakers Bristol Myers and Pfizer said on Thursday that they will make their blood thinner, Eliquis, ...

With regard to the choice of bone-protecting agent, denosumab (Xgeva) improved bone density and reduced fracture risk in a placebo-controlled trial involving men with non-metastatic HSPC. Denosumab ...

While Pfizer's dividend yield is clearly much higher than Merck's, both have relatively attractive yields today. And you ...

The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...